SCHEMBL2829434

SCHEMBL2829434

CCCn1c(C)c(C(=O)O)c2c(F)ccc(F)c2c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 12/20 0.44
CNR1 P21554 7/20 0.44
KDM4E B2RXH2 2/20 0.36
HSD17B10 Q99714 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
HPGD P15428 3/20 0.35
ALDH1A1 P00352 2/20 0.35
MEN1 O00255 2/20 0.35
CYP1A2 P05177 2/20 0.35
TSHR P16473 2/20 0.35
MAPK1 P28482 2/20 0.35
CYP2C19 P33261 2/20 0.35
KMT2A Q03164 2/20 0.35
NR1I2 O75469 1/20 0.35
MAPT P10636 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
VDR P11473 1/20 0.35
GMNN O75496 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2831862 0.84 CNR2 (0.46) CNR2CNR1KDM4EHSD17B10HPGD
SCHEMBL2834290 0.74 MEN1 (0.49) CNR2CNR1KDM4EHPGDALDH1A1
SCHEMBL2832433 0.73 LMNA (0.38) CNR2CNR1KDM4EHPGDALDH1A1
SCHEMBL2832139 0.73 CNR2 (0.55) CNR2CNR1HPGDALDH1A1MEN1
SCHEMBL2677729 0.72 GAA (0.45) KDM4EHSD17B10HPGDALDH1A1MEN1
SCHEMBL2832144 0.70 ADORA2B (0.41) CNR2CNR1KDM4EADORA2BHPGD
SCHEMBL2830533 0.70 ADORA2B (0.43) HSD17B10ADORA2BHPGDALDH1A1MEN1
SCHEMBL2830796 0.70 CNR2 (0.39) CNR2CNR1KDM4EHSD17B10ADORA2B
SCHEMBL2031946 0.70 CNR2 (0.36) CNR2CNR1KDM4EHSD17B10ADORA2A
SCHEMBL2834309 0.69 CNR1 (0.39) CNR2CNR1KDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP claimed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US claimed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US claimed
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP disclosed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US disclosed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 CNR2 359/4885CNR1 361/4885KDM4E 2545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.